Effect of Plantago major on nonalcoholic fatty liver disease

Comparison of the effect of plantago major with placebo on liver enzymes in patients with nonalcoholic fatty liver disease(NAFLD): a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191006044993N1

Enrollment

Registered

2019-11-05

Start date

2019-10-23

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver Disease. Non Alcoholic Fatty Liver Disease

Interventions

Intervention 1: Intervention group:In the intervention group in addition to lifestyle training and in-person follow-up once every 2 weeks, the 500 mg capsule of Plantago major seed twice per day is g

Eligibility

Sex/Gender

All

Age

12 Years to 80 Years

Inclusion criteria

Inclusion criteria: Sono graphic report of Grade 1 and 2 fatty liver Increase in ALT> 40 Increase in AST>38 Ages 12 to 80 years

Exclusion criteria

Exclusion criteria: The patient's unwillingness to participate in the scheme Pregnancy & lactation Anti coagulant drugs consumption Thyroid diseases Spleen diseases Cirrhosis ,viral hepatitis and obstructive liver disese Treated dyslipidemia Overt Diabetes mellitus Lung diseases Taking any medication that affects liver metabolism and enzymes, including oral contraceptives, corticosteroids, salazines, etc.

Design outcomes

Primary

Measure	Time frame
Comprison of the Plantago major seed with Placebo on ALT enzyme(Alanin trasaminase) in Non Alcoholic Fatty Liver Disease (NAFLD). Timepoint: Onset, 6th and 12th week of study.(End of study). Method of measurement: Hitachi 912 instrument.;Comprison of the Plantago major seed with Placebo on AST enzyme(Aspartate transaminase) in Non Alcoholic Fatty Liver Disease (NAFLD). Timepoint: Liver enzymes measurement at baseline, 6th and 12th weeks (end of study). Method of measurement: Hitachi 912 instrument.	—

Measure

Time frame

Comprison of the Plantago major seed with Placebo on ALT enzyme(Alanin trasaminase) in Non Alcoholic Fatty Liver Disease (NAFLD). Timepoint: Onset, 6th and 12th week of study.(End of study). Method of measurement: Hitachi 912 instrument.;Comprison of the Plantago major seed with Placebo on AST enzyme(Aspartate transaminase) in Non Alcoholic Fatty Liver Disease (NAFLD). Timepoint: Liver enzymes measurement at baseline, 6th and 12th weeks (end of study). Method of measurement: Hitachi 912 instrument.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyede Ferdos Jazayeri

Iran University of Medical Sciences

sf.jazayeri46@gmail.com+98 21 7752 1303

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026